Heymen Steve, Scarlett Yolanda, Jones Kenneth, Ringel Yehuda, Drossman Douglas, Whitehead William E
UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Dis Colon Rectum. 2007 Apr;50(4):428-41. doi: 10.1007/s10350-006-0814-9.
This study was designed to determine whether biofeedback is more effective than diazepam or placebo in a randomized, controlled trial for patients with pelvic floor dyssynergia-type constipation, and whether instrumented biofeedback is necessary for successful training.
A total of 117 patients participated in a four-week run-in (education and medical management). The 84 who remained constipated were randomized to biofeedback (n=30), diazepam (n=30), or placebo (n=24). All patients were trained to do pelvic floor muscle exercises to correct pelvic floor dyssynergia during six biweekly one-hour sessions, but only biofeedback patients received electromyography feedback. All other patients received pills one to two hours before attempting defecation. Diary data on cathartic use, straining, incomplete bowel movements, Bristol stool scores, and compliance with homework were reviewed biweekly.
Before treatment, the groups did not differ on demographic (average age, 50 years; 85 percent females), physiologic or psychologic characteristics, severity of constipation, or expectation of benefit. Biofeedback was superior to diazepam by intention-to-treat analysis (70 vs. 23 percent reported adequate relief of constipation 3 months after treatment, chi-squared=13.1, P<0.001), and also superior to placebo (38 percent successful, chi-squared=5.7, P=0.017). Biofeedback patients had significantly more unassisted bowel movements at follow-up compared with placebo (P=0.005), with a trend favoring biofeedback over diazepam (P=0.067). Biofeedback patients reduced pelvic floor electromyography during straining significantly more than diazepam patients (P<0.001).
This investigation provides definitive support for the efficacy of biofeedback for pelvic floor dyssynergia and shows that instrumented biofeedback is essential to successful treatment.
本研究旨在通过一项随机对照试验,确定生物反馈疗法对于盆底失协调型便秘患者是否比地西泮或安慰剂更有效,以及仪器辅助生物反馈对于成功训练是否必要。
共有117名患者参加了为期四周的导入期(教育和药物管理)。84名仍有便秘症状的患者被随机分为生物反馈组(n = 30)、地西泮组(n = 30)或安慰剂组(n = 24)。所有患者均接受了盆底肌肉锻炼训练,以在六周内每两周进行一次的一小时疗程中纠正盆底失协调,但只有生物反馈组患者接受了肌电图反馈。所有其他患者在尝试排便前一到两小时服用药丸。每两周审查一次关于泻药使用、用力排便、排便不完整、布里斯托大便评分以及家庭作业依从性的日记数据。
治疗前,各组在人口统计学特征(平均年龄50岁;85%为女性)、生理或心理特征、便秘严重程度或获益期望方面无差异。意向性分析显示生物反馈疗法优于地西泮(治疗后3个月,70%对23%报告便秘得到充分缓解,卡方检验=13.1,P<0.001),也优于安慰剂(成功率38%,卡方检验=5.7,P = 0.017)。与安慰剂组相比,生物反馈组患者在随访时自主排便次数显著更多(P = 0.005),生物反馈组优于地西泮组有一定趋势(P = 0.067)。生物反馈组患者在用力排便时盆底肌电图的降低幅度显著大于地西泮组患者(P<0.001)。
本研究为生物反馈疗法治疗盆底失协调的疗效提供了确凿支持,并表明仪器辅助生物反馈对于成功治疗至关重要。